CTXR vs. REGN
CTXR (Citius Pharmaceuticals, Inc.) and REGN (Regeneron Pharmaceuticals, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, CTXR returned -59.73%/yr vs 2.91%/yr for REGN. At a 0.12 correlation, their price movements are largely independent.
Performance
CTXR vs. REGN - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CTXR achieves a -25.01% return, which is significantly lower than REGN's -13.68% return.
CTXR
- 1D
- 3.81%
- 1M
- 7.91%
- 6M
- -34.36%
- YTD
- -25.01%
- 1Y
- -62.65%
- 3Y*
- -72.97%
- 5Y*
- -59.73%
- 10Y*
- —
REGN
- 1D
- -0.51%
- 1M
- 8.56%
- 6M
- -16.35%
- YTD
- -13.68%
- 1Y
- 17.69%
- 3Y*
- -2.23%
- 5Y*
- 2.91%
- 10Y*
- 6.15%
CTXR vs. REGN - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
CTXR Citius Pharmaceuticals, Inc. | -25.01% | -80.57% | -78.85% | -4.24% | -48.70% | 50.98% | -0.00% | -1.92% | -72.63% | -30.91% |
REGN Regeneron Pharmaceuticals, Inc. | -13.68% | 8.96% | -18.90% | 21.73% | 14.25% | 30.72% | 28.66% | 0.53% | -0.65% | -24.35% |
Correlation
The correlation between CTXR and REGN is 0.13, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.13 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.17 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.18 |
Correlation (All Time) Calculated using the full available price history since Jul 6, 2017 | 0.12 |
Fundamentals
CTXR:
$6.51M
REGN:
$68.46B
CTXR:
-$2.57
REGN:
$41.16
CTXR:
2.14
REGN:
4.79
CTXR:
0.21
REGN:
2.28
CTXR:
$5.61M
REGN:
$14.92B
CTXR:
$3.82M
REGN:
$12.61B
CTXR:
-$57.36M
REGN:
$5.74B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CTXR vs. REGN — Risk / Return Rank
CTXR
REGN
CTXR vs. REGN - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Citius Pharmaceuticals, Inc. (CTXR) and Regeneron Pharmaceuticals, Inc. (REGN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CTXR | REGN | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.21 | ||
| Sortino ratioReturn per unit of downside risk | -1.77 | ||
| Omega ratioGain probability vs. loss probability | 0.92 | 1.13 | -0.21 |
| Calmar ratioReturn relative to maximum drawdown | -0.91 | 0.75 | -1.66 |
| Martin ratioReturn relative to average drawdown | -1.35 | 1.91 | -3.26 |
Loading charts...
Drawdowns
CTXR vs. REGN - Drawdown Comparison
The maximum CTXR drawdown since its inception was -99.66%, which is greater than REGN's maximum drawdown of -91.81%. Use the drawdown chart below to compare losses from any high point for CTXR and REGN.
Loading charts...
Drawdown Indicators
| CTXR | REGN | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.66% | -91.81% | -7.85% |
Max Drawdown (1Y)Largest decline over 1 year | -71.04% | -25.85% | -45.19% |
Max Drawdown (3Y)Largest decline over 3 years | -98.30% | -59.69% | -38.61% |
Max Drawdown (5Y)Largest decline over 5 years | -99.07% | -59.69% | -39.38% |
Max Drawdown (10Y)Largest decline over 10 years | — | -59.69% | — |
Current DrawdownCurrent decline from peak | -99.63% | -44.25% | -55.38% |
Average DrawdownAverage peak-to-trough decline | -80.08% | -42.46% | -37.62% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 47.60% | 10.17% | +37.43% |
Volatility
CTXR vs. REGN - Volatility Comparison
Citius Pharmaceuticals, Inc. (CTXR) has a higher volatility of 16.99% compared to Regeneron Pharmaceuticals, Inc. (REGN) at 7.78%. This indicates that CTXR's price experiences larger fluctuations and is considered to be riskier than REGN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CTXR | REGN | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 16.99% | 7.78% | +9.21% |
Volatility (6M)Calculated over the trailing 6-month period | 74.06% | 22.20% | +51.86% |
Volatility (1Y)Calculated over the trailing 1-year period | 104.28% | 33.07% | +71.21% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 93.63% | 30.84% | +62.79% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 95.77% | 32.12% | +63.65% |
Dividends
CTXR vs. REGN - Dividend Comparison
CTXR has not paid dividends to shareholders, while REGN's dividend yield for the trailing twelve months is around 0.55%.
| Position | TTM | 2025 |
|---|---|---|
CTXR Citius Pharmaceuticals, Inc. | 0.00% | 0.00% |
REGN Regeneron Pharmaceuticals, Inc. | 0.55% | 0.46% |
Financials
CTXR vs. REGN - Financials Comparison
This section allows you to compare key financial metrics between Citius Pharmaceuticals, Inc. and Regeneron Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
CTXR and REGN have a correlation of 0.13, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CTXR has higher volatility (16.99%) compared to REGN (7.78%). In terms of maximum drawdown, CTXR dropped -99.66% vs REGN's -91.81%.
REGN currently has the higher Sharpe Ratio (0.59 vs -0.62), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for CTXR and REGN
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer